Expressions of c-Cbl,Cbl-b, and epidermal growth factor receptor in gastric carcinoma and their clinical significance
Qian Dong(Liaoning Cancer Hospital & Institute), Linlin Li(Liaoning Cancer Hospital & Institute), Xiujuan Qu(First Hospital of China Medical University), Kezuo Hou(First Hospital of China Medical University), Yunpeng Liu(Shenyang Institute of Automation)
Cited by 9
Related Papers
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission
|New England Journal of Medicine|2020|432